Nyxoah receives European CE Mark approval for the Genio™ system to treat sleep apnea - Gilde Healthcare

Nyxoah receives European CE Mark approval for the Genio™ system to treat sleep apnea

March 19, 2019

Utrecht, The Netherlands and Mont-Saint-Guibert, Belgium – Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio™ system in Europe. The Genio™ system is the world’s first and only battery-free, leadless and minimally invasive neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation for moderate to severe obstructive sleep apnea (OSA) patients who have failed conventional therapy.

The CE Mark approval was based on the BLAST OSA (BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea) clinical study, a prospective study that evaluated the safety and performance of the Genio™ system in 7 centers in France and Australia.

“Patients from the BLAST OSA study show a major improvement in their sleep apnea symptoms and their Quality of Life” said Enrique Vega, Chief Executive Officer of Nyxoah.

Robert Taub, Chairman of Nyxoah said: “The sleep community is looking for alternative solutions for OSA patients who refuse currently available therapies or are not compliant. Having now received CE mark, Nyxoah’s Genio™ system is well on its way to fulfil this need”.

About Nyxoah

Nyxoah S.A., headquarted in Mont-Saint-Guibert – Belgium, is a healthtech company focused on the development of innovative, neurostimulation-based solutions and services for sleep related disorders. Nyxoah S.A. was co-founded in 2009 by Robert Taub. For more information, please visit www.nyxoah.com.

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a private equity fund. Gilde Healthcare’s venture & growth capital fund invests in healthtech and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds...
May 20, 2022

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
May 19, 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding...
May 4, 2022